California State Teachers Retirement System raised its position in ABIOMED, Inc. (NASDAQ:ABMD) by 1.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 74,003 shares of the medical equipment provider’s stock after purchasing an additional 852 shares during the period. California State Teachers Retirement System owned 0.16% of ABIOMED worth $13,164,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Nomura Holdings Inc. increased its holdings in ABIOMED by 95.5% in the second quarter. Nomura Holdings Inc. now owns 7,709 shares of the medical equipment provider’s stock worth $2,043,000 after purchasing an additional 3,765 shares in the last quarter. Nuveen Asset Management LLC increased its stake in shares of ABIOMED by 17,845.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 197,759 shares of the medical equipment provider’s stock valued at $51,514,000 after acquiring an additional 196,657 shares in the last quarter. CIBC Asset Management Inc increased its stake in shares of ABIOMED by 2.1% in the 2nd quarter. CIBC Asset Management Inc now owns 4,093 shares of the medical equipment provider’s stock valued at $1,066,000 after acquiring an additional 85 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of ABIOMED by 13.3% during the 3rd quarter. SG Americas Securities LLC now owns 8,144 shares of the medical equipment provider’s stock valued at $1,449,000 after acquiring an additional 958 shares during the period. Finally, Commerce Bank acquired a new position in shares of ABIOMED during the 2nd quarter valued at $330,000. Hedge funds and other institutional investors own 90.68% of the company’s stock.

ABMD has been the topic of several research analyst reports. Leerink Swann increased their target price on shares of ABIOMED from $195.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. TheStreet downgraded shares of ABIOMED from a “b-” rating to a “c+” rating in a research note on Thursday, August 22nd. ValuEngine upgraded shares of ABIOMED from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. William Blair reissued a “buy” rating on shares of ABIOMED in a research report on Monday, September 30th. Finally, BidaskClub upgraded ABIOMED from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $301.20.

Shares of ABMD stock opened at $191.15 on Wednesday. The firm has a market capitalization of $8.86 billion, a PE ratio of 48.20, a price-to-earnings-growth ratio of 1.72 and a beta of 0.32. The firm has a fifty day simple moving average of $195.93 and a two-hundred day simple moving average of $218.11. ABIOMED, Inc. has a 12 month low of $155.02 and a 12 month high of $364.31.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, October 31st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.93 by $0.10. The firm had revenue of $204.97 million for the quarter, compared to the consensus estimate of $206.45 million. ABIOMED had a net margin of 26.92% and a return on equity of 19.89%. The business’s revenue was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.09 earnings per share. Research analysts anticipate that ABIOMED, Inc. will post 4.32 EPS for the current year.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

See Also: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.